The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

Last updated: January 21, 2026
Sponsor: Thomas Jefferson University
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Biospecimen Collection

Pulmonary Artery-First Surgical Technique

Clinical Study ID

NCT05502523
22D.435
JT 19625
  • Ages > 18
  • All Genders

Study Summary

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Any patients 18 years of age or older with confirmed or suspected early-stage (stageI-III) NSCLC

  • Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy orsegmentectomy) as routine clinical care for their disease

Exclusion

Exclusion Criteria:

  • Previous cancer diagnosis within 5 years (except ductal carcinoma in situ [DCIS] ofthe breast, superficial bladder cancer, non-melanoma skin primary, other malignancythat does not require treatment).

  • Preoperative chemotherapy, immunotherapy, or radiation therapy

  • Receipt of perioperative blood transfusion

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Biospecimen Collection
Phase:
Study Start date:
August 31, 2022
Estimated Completion Date:
January 01, 2029

Study Description

PRIMARY OBJECTIVE:

I. To determine the association between sequence of surgical resection and postoperative ctDNA levels at specified time points.

SECONDARY OBJECTIVE:

I. To determine the associated between sequence of surgical resection and postoperative ctDNA level and clinical oncologic outcomes.

II. To assess disease-free survival and the role of circulating tumor DNA in disease recurrence in patients with resectable non-small cell lung cancer.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients undergo pulmonary vein first approach surgical procedure on day of surgery.

GROUP II: Patients undergo pulmonary artery first approach surgical procedure on day of surgery.

After completion of surgery, patients are followed up at day 1, day 7, days 7-28, 4 months, every 6 months for 2 years, then every 6 months for up to 5 years

Connect with a study center

  • Abington Memorial Hospital

    Abington, Pennsylvania 19001
    United States

    Site Not Available

  • Jefferson Health Northeast

    Philadelphia, Pennsylvania 19107
    United States

    Site Not Available

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania 19107
    United States

    Active - Recruiting

  • Asplundh Cancer Pavilion at Jefferson Health

    Willow Grove, Pennsylvania 19090
    United States

    Site Not Available

  • Abington Memorial Hospital

    Abington 5177773, Pennsylvania 6254927 19001
    United States

    Active - Recruiting

  • Jefferson Health Northeast

    Philadelphia 4560349, Pennsylvania 6254927 19107
    United States

    Active - Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia 4560349, Pennsylvania 6254927 19107
    United States

    Active - Recruiting

  • Asplundh Cancer Pavilion at Jefferson Health

    Willow Grove 5219619, Pennsylvania 6254927 19090
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.